论文部分内容阅读
[目的]探讨CEA、CA19-9和CA125联合检测对良恶性腹水鉴别诊断的价值。[方法]采用电化学免疫发光法检测腹水中CEA、CA19-9和CA125含量。[结果]与良性腹水组相比,恶性腹水组腹水中CEA、CA19-9和CA125含量均显著升高(P﹤0.01,P﹤0.05);与良性腹水组相比,恶性腹水组血清中CA125水平相比差异无统计学意义(P﹥0.05),而血清CEA、CA19-9水平显著升高(P﹤0.01)。3项联合检测对恶性腹水的灵敏度、特异性、准确性和阳性预测值分别为:88.8%、97.1%、92.7%和97.0%。[结论]3项联合检测可减少单项肿瘤标志物的局限性,对良恶性腹水的鉴别具有重要的临床意义。
[Objective] To investigate the value of combined detection of CEA, CA19-9 and CA125 in the differential diagnosis of benign and malignant ascites. [Method] The contents of CEA, CA19-9 and CA125 in ascites were detected by electrochemical immunoluminescence. [Results] Compared with benign ascites group, the levels of CEA, CA19-9 and CA125 in malignant ascites group were significantly increased (P <0.01, P <0.05). Compared with benign ascites group, the levels of CA125 There was no significant difference between the two groups (P> 0.05), while the levels of serum CEA and CA19-9 were significantly increased (P <0.01). The sensitivity, specificity, accuracy and positive predictive value of the three combined tests for malignant ascites were 88.8%, 97.1%, 92.7% and 97.0%, respectively. [Conclusion] The three combined tests can reduce the limitations of single tumor markers and have important clinical significance in the differential diagnosis of benign and malignant ascites.